Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Celldex Therapeutics, Inc. - Common Stock (NQ:CLDX)

19.95 -0.54 (-2.64%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,329,886
Open 20.03
Bid (Size) 18.98 (1)
Ask (Size) 24.00 (2)
Prev. Close 20.49
Today's Range 19.39 - 20.86
52wk Range 14.40 - 47.00
Shares Outstanding 66,344,236
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Celldex Reports First Quarter 2025 Financial Results and Provides Corporate Update
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Presents Histology Data from Phase 2 Study of Barzolvolimab in EoE Supporting Potential of Mast Depleting Agent in this Difficult to Treat Disease
Phase 2 study fully enrolled; data expected in 2H 2025 
From Celldex Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
-22.6%
-22.6%
1 Month
+5.3%
+5.3%
3 Month
-11.5%
-11.5%
6 Month
-20.1%
-20.1%
1 Year
-47.2%
-47.2%

More News

Read More
Analyst Expectations For Celldex Therapeutics's Future
Via Benzinga
Forecasting The Future: 6 Analyst Projections For Celldex Therapeutics
Via Benzinga
Demystifying Celldex Therapeutics: Insights From 6 Analyst Reviews
Via Benzinga
What Analysts Are Saying About Celldex Therapeutics Stock
Via Benzinga
This Kohl's Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Monday
Via Benzinga
7 Analysts Have This To Say About Celldex Therapeutics
Via Benzinga
This Microsoft Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Via Benzinga
Celldex Therapeutics to Present at Upcoming Investor Conferences
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Therapeutics Presents Positive Preclinical Data from Inflammatory Bispecific Antibody Program CDX-622 at AAAAI 2025
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Beyond The Numbers: 11 Analysts Discuss Celldex Therapeutics Stock
Via Benzinga
Analyst Expectations For Celldex Therapeutics's Future
Via Benzinga
Celldex Therapeutics Presents Positive Results from Barzolvolimab Phase 2 Studies in Patients with Chronic Urticaria Demonstrating Improved Disease Control and Quality of Life at AAAAI 2025
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Baidu, Informatica And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga
Jasper Therapeutics Skin Disorder Candidate Data Fails To Cheer Investors
Via Benzinga
A Closer Look at 10 Analyst Recommendations For Celldex Therapeutics
Via Benzinga
Celldex Initiates Phase 2 Study of Barzolvolimab in Atopic Dermatitis
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Announces First Patient Dosed in Phase 1 Healthy Volunteer Study of CDX-622, a Bispecific Antibody, for the Treatment of Inflammatory Diseases
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Therapeutics to Present at Upcoming Investor Conferences
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Announces Barzolvolimab Met All Primary and Secondary Endpoints with High Statistical Significance in Positive Phase 2 Study in Chronic Inducible Urticaria
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Announces Upcoming Late Breaking Oral Presentation of 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria at ACAAI 2024
From Celldex Therapeutics, Inc.
Via GlobeNewswire
This HP Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
Via Benzinga
Celldex Therapeutics Presents Landmark 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV 2024
From Celldex Therapeutics, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Celldex Therapeutics, Inc. - Common Stock publicly traded?
Yes, Celldex Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Celldex Therapeutics, Inc. - Common Stock trade on?
Celldex Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Celldex Therapeutics, Inc. - Common Stock?
The ticker symbol for Celldex Therapeutics, Inc. - Common Stock is CLDX on the Nasdaq Stock Market
What is the current price of Celldex Therapeutics, Inc. - Common Stock?
The current price of Celldex Therapeutics, Inc. - Common Stock is 19.95
When was Celldex Therapeutics, Inc. - Common Stock last traded?
The last trade of Celldex Therapeutics, Inc. - Common Stock was at 05/21/25 04:00 PM ET
What is the market capitalization of Celldex Therapeutics, Inc. - Common Stock?
The market capitalization of Celldex Therapeutics, Inc. - Common Stock is 1.32B
How many shares of Celldex Therapeutics, Inc. - Common Stock are outstanding?
Celldex Therapeutics, Inc. - Common Stock has 1B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.